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Finding new ways in the treatment of fatal parasitic diseases like the human sleeping sickness is a major challenge of biomedical research. The
growing body of knowledge about the biogenesis of the glycosome, a peroxisome-related organelle of trypanosomes, might allow defining novel
targets for drug development.
© 2005 Elsevier B.V. All rights reserved.Keywords: Glycosome; Peroxisome; Biogenesis; TrypanosomaFig. 1. Simplified scheme of the functional network of peroxin interactions at theAfrican trypanosomes are parasitic protozoa that cause
human sleeping sickness and livestock trypanosomias (Naga-
na disease). The incidence of the human disease may
approach 300,000 to 500,000 cases per year, and it is
invariably fatal if left untreated [1]. Since available drugs for
late-stage disease are inadequate due to high toxicity and
emerging resistance, new treatments are urgently required.
Previous research has unequivocally validated ‘compartmen-
tation of glycolysis’ as a target for design of new drugs [2]. In
contrast to human cells, the bloodstream-form trypanosome
harbours glycosomal key enzymes in unique subcellular
microbodies called glycosomes. Proper biogenesis and
maintenance of the peroxisome-related organelle and correct
targeting of glycolytic enzymes are essential to these parasites
[2]. So far, 33 proteins involved in peroxisome biogenesis,
collectively called peroxins, have been identified in mammals
and various yeast species. During the last years a number of
homologous peroxins could also be identified in Trypanosoma
brucei including PEX5, PEX14 and PEX2, all of which are
essential for import of glycosomal matrix enzymes [3–5].
According to the current import cycle model, PEX5 represents
the cytosolic receptor for all proteins carrying a peroxisomal
targeting signal Type 1 (PTS-1), the membrane bound PEX14
acts as a docking protein for the receptor, and the RING-
finger peroxin PEX2 may be involved in cargo translocation⁎ Tel.: +49 234 32 22033; fax: +49 234 32 14279.
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doi:10.1016/j.bbamcr.2005.12.004and/or facilitate release of PEX5 from the membrane for
another round of import (Fig. 1).glycosomal membrane. Previously known peroxins, PEX5, PEX14, PEX2 and
PEX19, the newly identified peroxins PEX6, PEX10 and PEX12 (Krazy and
Michels [6]) and the assumed peroxins PEX1, PEX3, PEX13 and PEX26
(dashed borders) are indicated by numbers.
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the group of Michels to identify three additional peroxins by
sequence similarities [6]. These are PEX10 and PEX12, two
membrane-bound RING-finger peroxins and the soluble AAA-
peroxin PEX6. Krazy and Michels demonstrated that RNAi
depletion of the newly identified peroxins affects survival of
both blood-form and insect-form trypanosomes. The essential
roles of these peroxins during the life cycle of the parasite make
these proteins suitable targets for drug development.
How could such potential inhibitors be designed? One
possibility is to screen for compounds which interfere
specifically with the complex network of protein–protein
interactions at the glycosomal membrane. It has been considered
already to abolish the docking step of the PTS1-receptor at the
peroxisomal membrane by blocking trypanosomal PEX14 [7].
The study of Krazy and Michels has now identified three key
players of the PEX5 import cycle acting downstream of the
docking event. Yeast studies suggested that the RING-finger
proteins PEX10, PEX12 and PEX2 function as a complex in
conjunction with membrane-bound PEX5 [8]. Therefore,
compounds which specifically interact with the binding sites
of RING-finger peroxins could abolish complex assembly and
result in a blockage of glycosomalmatrix enzyme import. Import
could also be inhibited by preventing the interactions of one or
more membrane-bound peroxins with PEX19, the shuttling
import receptor for membrane proteins, which has been
identified recently also in trypanosomes [9]. Another good
candidate for drug design is the AAA-peroxin PEX6. Recent
work suggested that the AAA-peroxins PEX1 and PEX6
dislocate the PTS1-receptor from the peroxisomal membrane
in an ATP-dependent manner [10]. As shown recently for
mammalian cells, abolishing the interaction between the N-
terminus of PEX6 and its membrane anchor PEX26 inhibits
peroxisomal protein import [11]. Another putative target within
the PEX6 sequence is the C-terminal ATP-binding domain. It
has been demonstrated in yeast and mammals that dislocation of
the PTS1-receptor from the peroxisomal membrane requires
ATPase activity of AAA-peroxins [10]. It is clear that further
characterization of the glycosomal import machinery will
increase the number of potential drug targets. Recently
developed in vitro assays for insertion and export of the PTS1-
receptor PEX5 [10,12] and the import of peroxisomal membrane
proteins [13] are useful to test such compounds in the first
instance.
All in all, the identification of three novel peroxins in
Trypanosoma brucei by Krazy and Michels [6] clearly supports
the view that the mechanisms of protein import into peroxi-
somes and glycosomes are conserved. However, the low-level
of sequence identity among human and trypanosomal peroxins
indicates that specific inhibitors can be designed which abolish
essential protein–protein interactions in trypanosomes without
harming human cells. Therefore, the results by Krazy and
Michels provide a valuable basis for future medical research.References
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